Related references
Note: Only part of the references are listed.Severe Pazopanib-Induced Hepatotoxicity: Clinical and Histologic Course in Two Patients
Samuel J. Klempner et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Targeted Therapies for Hepatocellular Carcinoma
Augusto Villanueva et al.
GASTROENTEROLOGY (2011)
Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
Chun-Fang Xu et al.
JOURNAL OF HEPATOLOGY (2011)
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
C-F Xu et al.
BRITISH JOURNAL OF CANCER (2010)
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
Michael Friedlander et al.
GYNECOLOGIC ONCOLOGY (2010)
Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non-Small-Cell Lung Cancer
Nasser Altorki et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
Thomas E. Hutson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Keith C. Bible et al.
LANCET ONCOLOGY (2010)
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
Fabio M. Iwamoto et al.
NEURO-ONCOLOGY (2010)
A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium
Sara K. Taylor et al.
ONCOLOGIST (2010)
New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
Lance Cowey
OncoTargets and Therapy (2010)
Acute hepatic failure following monotherapy with sunitinib for ovarian cancer
A. Taran et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Diagnosis, management and prevention of drug-induced liver injury
S. Verma et al.
GUT (2009)
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Drug-induced liver injury: insights from genetic studies
Raul J. Andrade et al.
PHARMACOGENOMICS (2009)
Sorafenib-Induced Liver Failure
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients A Meta-analysis
Shobha Rani Nalluri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1α
Farzin Forooghian et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2007)
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis
Xiaolei Zhu et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
DJ Hicklin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Angiogenesis-independent endothelial protection of liver: Role of VEGFR-1
J LeCouter et al.
SCIENCE (2003)
Role of angiogenesis in tumor growth and metastasis
J Folkman
SEMINARS IN ONCOLOGY (2002)
Molecular mechanisms of tumor angiogenesis and tumor progression
U Cavallaro et al.
JOURNAL OF NEURO-ONCOLOGY (2000)
Share Paper
